Baird Medical (BDMD) Stock Sinks 33% in After-Hours Trading
Baird Medical shares fell 33% after partner Alpmed filed US, EU applications for its IRE tumor-ablation system, targeting approvals in 2027.
Baird Medical's stock dropped a lot after a partner company filed paperwork for a new cancer treatment. When a partner moves forward on their own, it can mean less control or unclear plans for Baird.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.